4.7 Article

Enhancing Diagnostic Performance of Symptom-Based Criteria for Irritable Bowel Syndrome by Additional History and Limited Diagnostic Evaluation

Journal

AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume 111, Issue 10, Pages 1446-1454

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/ajg.2016.308

Keywords

-

Funding

  1. Leeds Teaching Hospitals Charitable Foundation [9R11/14-05]
  2. NIH [DK 92179]

Ask authors/readers for more resources

OBJECTIVES: Symptom-based criteria to diagnose irritable bowel syndrome (IBS) positively perform only modestly. Our aim was to assess whether including other items from the clinical history and limited diagnostic evaluation improves their performance. METHODS: We collected complete symptom, colonoscopy, and histology data from 318 consecutive, unselected adult patients with lower gastrointestinal (GI) symptoms in secondary care. All participants underwent colonoscopy, with relevant organic findings recorded. The reference standard used to define the presence of true IBS was patient-reported lower abdominal pain or discomfort associated with a change in bowel habit, in the absence of organic GI disease. Sensitivity, specificity, and positive and negative likelihood ratios (LRs), with 95% confidence intervals, were calculated for Rome III criteria, as well as for modifications, incorporating nocturnal stools, results of simple blood tests (hemoglobin and C-reactive protein (CRP)), measures of somatization, and/or affective disorders (hospital anxiety or depression scale (HADS) score). RESULTS: The sensitivity and specificity of the Rome III criteria for identifying IBS was 69.6%, and 82.0%, respectively, with positive and negative LRs of 3.87 and 0.37, respectively. Clinically useful enhancements in positive LRs were provided by combining Rome III criteria with: (a) high level of somatization (7.27); (b) normal hemoglobin and CRP with HADS score of >= 8 (5.04); (c) normal hemoglobin and CRP with a high level of somatization (7.56); or (d) no nocturnal passage of stool with a high level of somatization (17.3). Specificity was >= 95% with each of these modifications. CONCLUSIONS: Incorporating nocturnal stools, somatization, and affective disorders from the clinical history, and hemoglobin and CRP measurements, enhances the positive LR and specificity of symptom-based Rome III criteria for IBS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Gastroenterology & Hepatology

Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis

Brigida Barberio, David J. Gracie, Christopher J. Black, Alexander C. Ford

Summary: This study conducted a network meta-analysis to compare the relative efficacy of various biological therapies and small molecules in the treatment of luminal Crohn's disease. The results showed differences in the effectiveness of different drugs in inducing and maintaining clinical remission, and previous exposure to biologics also had an impact on treatment outcomes.
Article Education & Educational Research

Examiner perceptions of the MRCGP recorded consultation assessment for general practice licensing during COVID-19: cross-sectional study

Vanessa Botan, Despina Laparidou, Viet-Hai Phung, Peter Cheung, Adrian Freeman, Richard Wakeford, Meiling Denney, Graham R. R. Law, Aloysius Niroshan Siriwardena

Summary: This study evaluated examiner perceptions of the Recorded Consultation Assessment (RCA) as a replacement for the Clinical Skills Assessment (CSA) in the UK general practice licensing exam. The results showed that the RCA was considered feasible and broadly acceptable by examiners, although challenges were experienced in candidate case selection, case content, and judgments.

BMC MEDICAL EDUCATION (2023)

Letter Gastroenterology & Hepatology

Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply

Vivek C. Goodoory, Elspeth A. Guthrie, Cho Ee Ng, Christopher J. Black, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome--authors' reply

Vivek C. Goodoory, Cho E. Ng, Christopher J. Black, Alexander C. Ford

Summary: This article is associated with Goodoory et al papers. Click the link to access these articles.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Letter Gastroenterology & Hepatology

Relative Cost-effectiveness of Management Strategies for Uninvestigated Dyspepsia

Alexander C. Ford, Colin W. Howden

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Article Gastroenterology & Hepatology

A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care

Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford

Summary: The study suggests that diagnosing IBS according to the Rome IV criteria and conducting limited investigation is safe and durable. Among IBS patients, although 1 in 6 were referred again due to gastrointestinal symptoms, missed organic gastrointestinal disease occurred in only 1% of patients.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

Letter Gastroenterology & Hepatology

Substantial Variability in Placebo and Nocebo Responses Challenges the Validity of Network Meta-Analysis of Gastroparesis Pharmacotherapy Reply

Maria rosa Ingrosso, Christopher j. Black, Alexander c. Ford

GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Novel symptom clusters predict disease impact and healthcare utilisation in inflammatory bowel disease: Prospective longitudinal follow-up study

Christy Riggott, Keeley M. Fairbrass, Christopher J. Black, David J. Gracie, Alexander C. Ford

Summary: Using latent class analysis, this study identified novel clusters of patients with inflammatory bowel disease (IBD) and found that patients with higher gastrointestinal and psychological symptoms were at a higher risk of adverse disease outcomes and were also high-volume users of healthcare.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Editorial Material Gastroenterology & Hepatology

Editorial: Recognising the regional variations in profile of irritable bowel syndrome-better late than never! Authors' reply

Kee-Huat Chuah, Christopher J. Black, Vincent Tee, Sze-Zee Lim, Wen-Xuan Hian, Nur-Fazimah Sahran, Yeong-Yeh Lee, Sanjiv Mahadeva, Alexander C. Ford

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Review Gastroenterology & Hepatology

Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis

Vivek C. Goodoory, Mais Khasawneh, Christopher J. Black, Eamonn M. M. Quigley, Paul Moayyedi, Alexander C. Ford

Summary: This article conducted a meta-analysis to study the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). The study found that certain combinations of probiotics or strains may be beneficial for IBS, but the certainty of the evidence was low.

GASTROENTEROLOGY (2023)

Review Gastroenterology & Hepatology

Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis

Pierfrancesco Visaggi, Brigida Barberio, Giulio Del Corso, Nicola de Bortoli, Christopher J. Black, Alexander C. Ford, Edoardo Savarino

Summary: A network meta-analysis was conducted to compare the efficacy of different drugs for active eosinophilic esophagitis (EoE). The results showed that most available drugs were more effective than placebo in treating EoE. However, significant heterogeneity among the trials hindered the establishment of a solid therapeutic hierarchy.
Article Gastroenterology & Hepatology

Impact of Opioid Use on the Natural History of Inflammatory Bowel Disease: Prospective Longitudinal Follow-up Study

Christy Riggott, Keeley M. Fairbrass, Christian P. Selinger, David J. Gracie, Alexander C. Ford

Summary: The use of opioids in patients with inflammatory bowel disease (IBD) is associated with psychological comorbidity and an increased risk of intestinal resection, particularly with stronger formulations. Future studies should classify the risks of different opioids to develop reliable prescribing algorithms, and evaluate the effectiveness of addressing psychological factors as an opioid avoidance strategy in routine IBD care.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 12 months of longitudinal follow-up

Brigida Barberio, Keeley M. Fairbrass, David J. Gracie, Alexander C. Ford

Summary: In this 12-month longitudinal study, one-third of patients with IBD reported presence of Rome III IBS-type symptoms at any point in time. Reporting such symptoms was associated with significant impacts on psychological health and/or quality of life.

NEUROGASTROENTEROLOGY AND MOTILITY (2023)

Meeting Abstract Gastroenterology & Hepatology

Longitudinal follow-up study to determine durability of a diagnosis of Rome IV Irritable bowel syndrome in secondary care

Mais Khasawneh, Orla F. Craig, David J. Gracie, Christopher J. Black, Alexander C. Ford

No Data Available